Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052.

Abstract

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.

Keywords: monoclonal antibody; nirsevimab; palivizumab; pharmacokinetics; respiratory syncytial virus.

MeSH terms

  • Antibodies, Monoclonal
  • Antiviral Agents / therapeutic use
  • Child
  • Humans
  • Infant
  • Lung Diseases* / drug therapy
  • Respiratory Syncytial Virus Infections* / drug therapy
  • Respiratory Syncytial Virus Infections* / epidemiology
  • Respiratory Syncytial Virus, Human*
  • Seasons

Substances

  • nirsevimab
  • Antibodies, Monoclonal
  • Antiviral Agents

Grants and funding